Skip to main content
Premium Trial:

Request an Annual Quote

Nanostics ClarityDx Prostate

Nanostics has launched its ClarityDX Prostate test, which will be performed the company's lab in Edmonton, Alberta. The blood-based prostate cancer screening test is used to generate risk scores through analysis of biological and clinical biomarkers. The firm said the test provides critical information for men ages 40-75 years and helps physicians make better informed decisions whether a prostate biopsy is required following a high prostate-specific antigen test result. Nanostics said its research indicates adding ClarityDX to the patient care pathway can reduce unnecessary prostate biopsies by up to 35 percent and reduce healthcare costs. The firm also received a CE-IVD mark for the test in August 2022.